Some case-control studies showed significantly increased risk between ACE inhibitor usage and prostate cancer [15, 17], while a previous meta-analysis showed that ACE inhibitors or angiotensin-receptor blockers did not affect the occurrence of cancer [18]. This evidence concerns the gene ACE and prostate cancer.